Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a leading biopharmaceutical company based in China, focuses on innovative drug discovery and development. Founded in 2015, the company has rapidly established itself in the biotechnology sector, with its headquarters in Beijing and operational reach across major regions in China. Specialising in monoclonal antibodies and gene editing technologies, Biocytogen is renowned for its unique animal models that facilitate advanced preclinical research. The company’s commitment to innovation has positioned it as a key player in the global biopharmaceutical landscape, with notable achievements in therapeutic development and collaborations with various research institutions. With a strong emphasis on quality and scientific excellence, Biocytogen continues to drive advancements in the industry, contributing significantly to the future of healthcare solutions.
DitchCarbon Score
How does Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s reported carbon emissions
In 2022, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. reported greenhouse gas emissions data, although specific absolute emissions figures in kg CO2e were not disclosed. The company provided greenhouse gas emission intensity metrics, indicating approximately 200.0 kg CO2e per square metre and about 0.00043 kg CO2e per RMB1,000 expenditure. However, there is no available data on Scope 1, 2, or 3 emissions, nor any specific reduction targets or climate pledges. Biocytogen has not set any formal reduction initiatives or Science-Based Targets Initiative (SBTi) commitments, indicating a potential area for future development in their climate strategy. The absence of cascaded emissions data suggests that the company operates independently in its emissions reporting and climate commitments. Overall, while Biocytogen Pharmaceuticals has provided some insights into its emissions intensity, further transparency and commitment to reduction targets would enhance its climate accountability.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
